文献速递免疫规划

两剂四价HPV疫苗的长期免疫原性及基础接种五年后额外剂次的效果

Long term immunogenicity of two doses of the quadrivalent HPV vaccine and the effect of an additional dose given five years post-primary vaccination.
PubMed 文献 · Vaccine · 2025-10-30

研究纳入496名9-11岁接种两剂四价HPV疫苗的女孩,五年后随机分为加一剂组(2+1)和不加剂组。两剂组抗体至10年保持稳定,加剂组在7.5年和10年时抗体几何平均浓度更高(p<.0001),提示存在免疫记忆。

要点

  • 两剂四价HPV疫苗在9-11岁女孩中诱导的抗体至接种后10年仍可检出。
  • 基础接种五年后加一剂,可使7.5年和10年时抗体几何平均浓度高于两剂组。
  • 两剂组抗体水平至10年保持稳定,加剂后抗体提升提示免疫记忆存在。

核心结论

  • 9-11岁接种两剂四价HPV疫苗可诱导至接种后10年稳定的抗体水平,数年后再加一剂可增强抗体,提示存在免疫记忆。

研究设计与样本

  • 女孩(9-11岁)接种两剂四价HPV疫苗(Gardasil)共496名,在首剂后五年随机分为加一剂组(2+1)和不加剂组。
  • 采用M9ELISA法在基础接种后5年、7.5年和10年检测HPV 6/11/16/18型抗体几何平均浓度。

主要发现

  • 两个研究组在所有时间点均可检出针对四价HPV疫苗靶向型别的抗体。
  • 两剂组抗体水平至10年保持稳定,加一剂组在基础接种后7.5年和10年的几何平均浓度高于两剂组(p<.0001)。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Antibody persistence in girls (age 9-11 years) receiving two quadrivalent vaccine (4vHPV) doses and impact of an additional dose five years post-primary vaccination were assessed. METHODS: Girls vaccinated with two 4vHPV (Gardasil) doses (n = 496) were randomized to one- (2 + 1) or no-additional-dose groups five years post-first dose. Geometric mean concentrations (GMCs) for HPV types 6/11/16/18 were measured using M9ELISA at 5, 7.5, and 10 years post-primary vaccination. RESULTS: Antibodies to 4vHPV-targeted types persisted in all participants at each time point in both study arms. Compared to the 2-dose group that had stable antibody levels up to 10 years, GMCs were higher in the 2 + 1 group at 7.5 and 10 years post-primary vaccination (p < .0001). CONCLUSIONS: Two doses of 4vHPV administered at ages 9-11 confers stable antibody levels up to 10 years post-vaccination that can be enhanced with an additional dose given several years later, suggesting the presence of immune memory.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Sauvageau C, Ionescu IG, Ouakki M, et al. Long term immunogenicity of two doses of the quadrivalent HPV vaccine and the effect of an additional dose given five years post-primary vaccination. Vaccine. 2025. PMID: 41172933. doi:10.1016/j.vaccine.2025.127893

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。